myozyme 50mg powder for concentrate for solution for infusion
genzyme europe b.v., netherlands - alglucosidase alfa - powder for concentrate for solution for infusion - 5 mg/ml
myozyme 50mg powder for concentrate for solution for infusion
genzyme europe b.v., netherlands - alglucosidase alfa - powder for concentrate for solution for infusion - 5 mg/ml
cerezyme 400unit powder for solution for infusion vials
genzyme therapeutics ltd - imiglucerase - powder for solution for infusion - 400unit
uromitexan 100mg/ml solution for injection or infusion (4ml ampoule)
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products
uromitexan 100mg/ml solution for injection or infusion (10ml ampoule)
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products
myozyme
pharmacy retailing (nz) ltd t/a healthcare logistics - alglucosidase alfa 52.5mg; ; ; - powder for infusion concentrate - 50 mg/10ml - active: alglucosidase alfa 52.5mg excipient: dibasic sodium phosphate heptahydrate mannitol monobasic sodium phosphate monohydrate nitrogen polysorbate 80 - myozyme is indicated for the long - term treatment of patients with a confirmed diagnosis of pompe disease (acid alfa - glucosidase deficiency).
myozyme 50 mg powder for concentrate for solutions for infusion (iv)
n/a; importer: sanofi-aventis philippines, inc.; distributor: sanofi-aventis philippines, inc. - alglucosidase alfa - powder for concentrate for solutions for infusion (iv) - 50 mg
myozyme powder for solution
sanofi genzyme, a division of sanofi-aventis canada inc - alglucosidase alfa - powder for solution - 50mg - alglucosidase alfa 50mg - enzymes
myozyme
sanofi b.v. - alglucosidase alfa - glycogen storage disease type ii - other alimentary tract and metabolism products, - myozyme is indicated for long-term enzyme-replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid-α-glucosidase deficiency).in patients with late-onset pompe disease the evidence of efficacy is limited.
noradrenaline (tartrate) aguettant 2mg/ml (sulfites free), concentrate for sol for infusion (4ml)
laboratoire aguettant 1 rue alexander fleming, 69007 lyon, france - norepinephrine - concentrate for solution for infusion - norepinephrine 2 mg/ml - cardiac therapy